Heron Therapeutics Inc (OQ:HRTX)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 4242 Campus Point Court, Suite 200
SAN DIEGO CA 92121
Tel: N/A
Website: https://www.herontx.com
IR: See website
<
Key People
Adam Morgan
Chairman of the Board
Lisa Peraza
Vice President
Craig Alexander Collard
Chief Executive Officer, Director
Ira Duarte
Chief Financial Officer, Principal Accounting Officer
William P. Forbes
Executive Vice President, Chief Development Officer
Thomas B. Ottoboni
Senior Vice President - Pharmaceutical and Translational Sciences, Chief Scientific Officer
Sean T. Ristine
Senior Vice President of Human Resources
Robert Sullivan
Senior Vice President
Jason Grillot
Vice President of Sales and Marketing
John Arthur
Vice President - Manufacturing and Supply
   
Business Overview
Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF and APONVIE. HTX- ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the IV formulation of a NK1 receptor antagonist indicated for postoperative nausea and vomiting (PONV). Its products are distributed in the United States.
Financial Overview
For the three months ended 31 March 2024, Heron Therapeutics Inc revenues increased 17% to $34.7M. Net loss decreased 90% to $3.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Sales and marketing - Balancing value decrease of 42% to $10.6M (expense), Labor & Related Expenses in R&D decrease of 65% to $2.5M (expense).
Employees: 126 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $502.06M as of Mar 31, 2024
Annual revenue (TTM): $132.10M as of Mar 31, 2024
EBITDA (TTM): -$79.48M as of Mar 31, 2024
Net annual income (TTM): -$80.95M as of Mar 31, 2024
Free cash flow (TTM): -$44.73M as of Mar 31, 2024
Net Debt Last Fiscal Year: $78.02M as of Mar 31, 2024
Shares outstanding: 150,653,158 as of May 2, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.